DHR vs TWST
DHR: Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring, product identification, and healthcare globally. TWST: Twist Bioscience leverages a proprietary silicon-based platform to mass-produce high-quality synthetic DNA for applications in therapeutics, diagnostics, and research.
Side-by-side fundamentals
| Metric | DHR | TWST | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $207.44 | $123.12 | |
| Market cap as of 2026-08-12 | $145.8B | $7.7B | |
| P/E as of 2026-08-12 | 36.20 | n/a | |
| PEG as of 2026-08-12 | 3.74 | -1.06 | TWST lower |
| Net margin as of 2026-08-12 | +15.9% | -31.7% | DHR higher |
| Gross margin as of 2026-08-12 | +58.6% | +52.0% | DHR higher |
| Operating margin as of 2026-08-12 | +20.4% | -33.6% | DHR higher |
| ROE as of 2026-08-12 | +7.7% | -29.9% | DHR higher |
| ROA as of 2026-08-12 | +4.7% | -20.8% | DHR higher |
| Debt / equity as of 2026-08-12 | 0.51 | 0.00 | TWST lower |
| Revenue growth (YoY) as of 2026-08-12 | +4.6% | +19.2% | TWST higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | n/a | |
| Dividend yield as of 2026-08-12 | +0.8% | n/a | |
| Beta as of 2026-08-12 | 0.78 | 2.23 | |
| 1-year return as of 2026-08-11 close | +3.8% | +345.6% | TWST higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.